Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
254 results about "Pancreatic beta Cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method of forming pancreatic beta cells from mesenchymal cells
InactiveUS20050208029A1Easy to separateBiocidePancreatic cellsScreening methodBULK ACTIVE INGREDIENT
It is intended to provide a method of forming pancreatic β cells from mesenchymal cells characterized by comprising using mammal-origin mesenchymal cells as starting cells, culturing these cells in the presence of, for example, a pancreatic β cell-forming agent, and selecting and separating the thus obtained pancreatic βcells with the use of a gene expressed specifically in such cells as a selection marker; a remedy for glucose intolerance which comprises pancreatic β cells obtained by the above method as the active ingredient; a pancreatic β cell-forming agent such as a cytokine to be used in the above method; a method of screening a candidate compound promoting the formation of pancreatic β cells from mesenchymal cells; and a pancreatic β cell formation promoter obtained by this screening method.
Owner:OTSUKA PHARM CO LTD
Thyrotropin-Releasing Hormone Analogs and Method of Use
InactiveUS20080249028A1Modulating blood glucose levelMetabolism disorderMicrobiological testing/measurementAcute hyperglycaemiaThyrotropin-Releasing Hormone Analogue
The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancreatic beta cell malfunction, and hyperglycemia-related malfunction are preferably treated or prevented.
Owner:PROSPECT CHARTERCARE +1
Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems
The invention relates to methods that allow for the efficient differentiation to form pancreatic endoderm cells from pluripotent stem cells such as human embryonic stem cells and definitive endoderm cells. The invention is directly applicable to the ultimate generation of pancreatic beta cells that could be used as part of a therapy to treat or even cure diabetes. Additionally, the present invention may be used to generate liver endoderm cells from human embryonic stem cells and definite endoderm cells as well. This invention relates to a method for generating definitive endoderm and pancreatic endoderm cells from stem cells, preferably human embryonic stem cells using defined media in the absence of feeder cells. A simply two step procedure to provide pancreatic endoderm cells from embryonic stem cells represents further embodiments of the present invention.
Owner:UNIV OF GEORGIA RES FOUND INC
Compositions and methods for glycogen synthesis
InactiveUS20050176827A1Function increaseIncrease insulin sensitivityBiocideOrganic active ingredientsCysteine thiolateTryptophan
A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning. Preferably, the composition of bio-active compounds includes a combination of 4-hydroxyisoleucine with at least one amino acid selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate and tyrosine. In one presently preferred embodiment of the present invention, the combination is derived, isolated, and / or extracted from fenugreek seeds. Methods for using a novel composition of bio-active compounds from fenugreek seed for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning are also disclosed, wherein methods comprise the steps of: (1) providing an effective amount of a composition of bio-active compounds derived, isolated, and / or extracted from fenugreek seeds; and (2) administering the composition to a human or animal.
Owner:TSI INC
Monitoring two dimensions of diabetes pathogenesis seperately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development
InactiveUS20060280682A1Improve responseReduce sensitivityCompounds screening/testingDisease diagnosisDisease riskDisease progression
Provided are methods for determining concurrently with a simple, minimally invasive test, the adequacy of pancreatic beta-cell compensation and / or the presence of tissue insulin resistance in a subject human or an experimental animal. The methods allow for the determination of a subject's or experimental animal's susceptibility to developing type 2 diabetes mellitus (DM2) or to progression to more advanced forms of DM2. Among other uses, the methods allow for diagnostic classification of subjects for decisions regarding therapeutic interventions, clinical differentiation between type 1 DM and DM2, clinical monitoring of treatments intended to reduce risk of developing DM2 in non-diabetic subjects, clinical monitoring of agents intended to improve existing DM2 and to prevent progression of DM2, clinical development and testing of new compounds, candidate agents, or candidate therapies for preventing progression to DM2 or disease progression in existing DM2, and preclinical screening of candidate agents or candidate therapies in experimental animals to identify and characterize agents having insulin-sensitizing properties, pancreatic stimulatory or regenerative properties or other desirable actions.
Owner:RGT UNIV OF CALIFORNIA
Method, system and apparatus for control of pancreatic beta cell function to improve glucose homeostasis and insulin production
The present invention provides methods, systems and apparatuses for effecting excitation or inhibition of small sensory nerve fibers, such as C-afferent fibers, by electrical stimulation of nerves innervating the pancreas in diabetic subjects. In an aspect the methods are directed to effecting insulin production and for the treatment of diabetes. This invention includes a closed or open loop feedback control system in which biomarker levels are monitored in order to direct electrical stimulation. An implantable or external neural stimulation device is also provided.
Owner:NEURAL DIABETES
Multipotent stem cells derived from human adipose tissue and cellular therapeutic agents comprising the same
ActiveUS20070110729A1High proliferation ratePositive immunological responsesBiocideNervous disorderCartilage cellsSerum free media
This invention relates to human adipose tissue-derived multipotent adult stem cells. More particularly, the invention relates to human adipose tissue-derived multipotent stem cells, which can be maintained in an undifferentiated state for a long period of time by forming spheres and have high proliferation rates, as well as methods for isolating and maintaining the adult stem cells, and methods for differentiating the multipotent adult stem cells into nerve cells, fat cells, cartilage cells, osteogenic cells and insulin-releasing pancreatic beta-cells. Also, the invention relates to cellular therapeutic agents for treating osteoarthritis, osteoporosis and diabetes and for forming breast tissue, which contain the differentiated cells or the adult stem cells. Although the multipotent stem cells are adult stem cells, they have the ability to differentiate into osteogenic cells, nerve cells, astrocytes, fat cells, chrondrogenic cells or insulin-releasing pancreatic beta-cells, and so are effective in treating osteoporosis, osteoarthritis, nerve disease, diabetes, etc. Also, the stem cells form spheres in a serum-free medium containing CORM-2, and thus can be maintained in an undifferentiated state for a long period of time. Also, the stem cells have very high proliferation rates. Accordingly, the stem cells are useful as cellular therapeutic agents.
Owner:RNL BIO
Multipotent stem cells derived from human adipose tissue and cellular therapeutic agents comprising the same
ActiveUS7807461B2High proliferation ratePositive immunological responsesNervous disorderSkeletal disorderSerum free mediaBrown adipose tissue
Owner:RNL BIO
Induction of the formation of insulin-producing cells via gene transfer of pancreatic beta-cell-associated transcriptional factor
The present invention provides a method of inducing the formation of insulin-producing cells which comprises transferring a pancreatic β-cell associated transcriptional factor gene into the pancreas to induce the formation of insulin-producing cells. The pancreatic β-cell associated transcriptional factor gene is transferred into the pancreatic tissue stem cells by the ICBD injection without ligating the common bile ducts and thus the formation of insulin-producing cells is induced. In the present invention, pdx-1, neurogenin3, etc. are used as such pancreatic β-cell associated transcriptional factor gene and an adenoviral vector with the use of the Cre-loxP recombination system, etc. is used as a vector for transferring the pancreatic β-cell associated transcriptional factor gene into the pancreas. The method of the invention enables regeneration therapy for diabetes mellitus by inducing the formation of insulin-producing cells.
Owner:JAPAN SCI & TECH CORP
Prevention and/or treatment of diabetes mellitus by pharmacologically inhibiting pancreatic beta-cell O-linked protein glycosylation and/or pancreatic beta-cell p135 O-glycosylation
The present invention demonstrates a method for inhibiting O-linked protein glycosylation in a tissue or cell, comprising the step of contacting said tissue or cell with (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propy- l)amino] diazen-ium-1,2-diolate or a derivative thereof. The present invention is also directed to a method of treating or inhibiting the onset of diabetes mellitis in an individual in need of such treatment, comprising the step of admininstering to said individual a pharmacological dose of a compound which inhibiting O-linked protein glycosylation in a tissue or cell of said individual. Further, the present invention provides a pharmaceutical composition, comprising (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propyl)amino] diazen-ium-1,2-diolate and a pharmaceutically acceptable carrier or a derivative thereof.
Owner:UAB RES FOUND
Cyclohexane analogues as gpr119 agonists
This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and / or insulin sensitizers.
Owner:THE ASAN FOUND
Use of ingap for reversing diabetes
InactiveUS20060009516A1Prevent autoimmune destructionPrevention of autoimmune destructionBiocidePeptide/protein ingredientsIslet cellsNeogenesis
The present invention relates to a method to stimulate reversal of a diabetic state in a patient; a method to prevent autoimmune destruction of new insulin-producing cells (pancreatic beta-cells) in a patient; a method to promote survival of the newly regenerated insulin-producing cells (pancreatic beta-cells); and an in vivo method for the induction of islet cell neogenesis and new islet formation and the prevention of autoimmune destruction of said new cells.
Owner:MCGILL UNIV
Co-culture compositions and methods
Co-culture compositions and methods are described for identifying agents that modulate a cellular phenotype, particularly of neurons or pancreatic beta cells are provided herein, where the methods include co-culturing differentiated cells, wherein at least one of the cell-types are derived from human induced pluripotent stem cells from a subject having or predisposed to a neurodegenerative or metabolic disorder. Co-culture compositions of differentiated cells from two different human subjects are also described.
Owner:IPIERIAN
Treatment of metabolic disorders in feline animals
ActiveUS20150164856A1Reduce doseReduce frequencyBiocideNervous disorderAcute hyperglycaemiaDyslipidemia
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and / or Syndrome X (metabolic syndrome) and / or loss of pancreatic beta cell function and / or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and / or maintained.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Novel heterocycles
InactiveUS20070167413A1Useful in treatmentOrganic active ingredientsBiocideRESPIRATORY DISTRESS SYNDROME ADULTContact dermatitis
The present invention relates to novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel hetereocycles of the general formula (I). Also included is a method of treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.
Owner:ORCHID RES LAB +1
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
InactiveUS6972319B1Good potencyStimulate insulin releasePeptide/protein ingredientsReceptors for hormonesDiseaseMammal
This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP / PACAP-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.
Owner:BAYER CORPORATION +1
Coxsackie B virus and type 1 diabetes
InactiveUS20100047273A1Slow and delay and progressionSlow and delay symptomSsRNA viruses positive-senseSugar derivativesCOXSACKIE A VIRUSAutoimmune responses
Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. Coxsackie virus has been detected in human pancreatic beta cells and causes insulitis. This non-destructive islet inflammation does not itself cause diabetes, but this disease will occur if viral infection is followed by a separate autoimmune response. The insulitis is mediated mainly by natural killer cells. Islets from coxsackie virus positive samples displayed reduced insulin secretion in response to glucose and other secretagogues. Virus extracted from positive islets was able to infect beta cells from human islets of non-diabetic donors, causing viral inclusions and signs of pyknosis.
Owner:RAPPUOLI RINO +2
Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules
InactiveUS20160208215A1Improve the level ofEffectively lead to differentiationPancreatic cellsCulture processProgenitorType i receptor
The present invention relates to differentiation of stem cells into a homogeneous endocrine progenitor cell population suitable for further differentiation into pancreatic beta-cells. The present invention provides methods for obtaining NGN3 / NKX2.2 double positive endocrine progenitor cells by exposing precursor cells to a TGF-β type I receptor inhibitor, a BMP antagonist, an adenylate cyclase activator and nicotinamide and / or exposing to the precursor cells to a selection of small molecules.
Owner:NOVO NORDISK AS +1
Method, system and apparatus for control of pancreatic beta cell function to improve glucose homeostasis and insulin production
Owner:NEURAL DIABETES
Gene expression in peripheral blood mononuclear cells from children with diabetes
InactiveUS20080227709A1Peptide/protein ingredientsLibrary screeningPeripheral blood mononuclear cellWhite blood cell
The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Cyclic Peptide Analogues For Non-Invasive Imaging of Pancreatic Beta-Cells
InactiveUS20120100070A1Rapid enzymatic degradationImprove performanceUltrasonic/sonic/infrasonic diagnosticsBiocideCyclic peptideHalf-life
Compositions, methods of using and methods of making a cyclic peptide analog imaging agent that includes at least portions of a peptide or protein that binds specifically to the GLP-1 receptor (GLP-1R) and the cyclic analog has one or more conformational restrictions including, but not limited to, lactam bridges, disulfide bridges, hydrocarbon bridges, and their combinations, salts and derivatives thereof wherein the cyclic analog is more stable than a non-cyclic analog when incubated in the presence of enzymes that degrade GLP-1 and have an increased serum half-live, wherein the cyclic analog comprises at least a portion of a GLP-1 peptide or at least a portion of an Exendin peptide salts, derivatives or combinations thereof.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
Owner:BAYER HEALTHCARE LLC
Construction method for mouse model with conditionally deleted Tmem30a genes and with pancreatic beta cells and application
The invention discloses a construction method for a mouse model with conditionally deleted Tmem30a genes and with pancreatic beta cells and an application. The construction method comprises the following steps: constructing a conditionally deleted Tmem30a gene homozygote mouse, wherein the two ends of one or more exon of the Tmem30a genes are inserted into homonymous arrayed loxP locus; mating the mouse with pancreatic beta cell specific transgenic mouse Ins2-Cre, thereby acquiring the mouse model with conditionally deleted Tmem30a genes and with pancreatic beta cells. The mouse with conditionally deleted Tmem30a genes and with pancreatic beta cells shows glucose intolerance and poor insulin sensitivity. The mouse model can be used as a diabetes research model.
Owner:成都基康医药科技有限公司
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP / PACAP-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.
Owner:BAYER HEALTHCARE LLC
Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response
ActiveUS20170362572A1Gastrointestinal cellsMicrobiological testing/measurementInduced pluripotent stem cellIslet cells
The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.
Owner:JANSSEN BIOTECH INC
Method for establishing SD mouse fat and diabetes research model through diet and STZ induction
InactiveCN109221011AExplain stabilityEasy to get materialsOrganic active ingredientsAnimal husbandryAnimal scienceHuman type
The invention provides a method for establishing an SD mouse fat and diabetes research model through diet and STZ induction. Through high-fat feed and STZ induction, the attacking characteristics of fat and diabetes of humans are induced, and an animal model for establishing pathogenesis of fat and type-2-diabetes caused by insulin resistance and partial defects of pancreatic beta cells is provided. Mice are divided into a normal control group, a fat group and a diabetes group, and each group has six SD male mice. The high-fat feed is adopted for feeding mice for eight weeks, a pure-fat insulin resistance model is induced, after the mice are fed with the high-fat feed for eight weeks, injection of STZ small doze in batch is conducted, and establishment of the diabetes animal model is induced. The method can better simulate the attacking characteristics of human type-2-diabetes caused by improper diet and enjoinment factors currently, and compared with other modeling, the method has better scientific significance of clinical and fundamental research combination.
Owner:任慧雯
Insulin pump
The present invention relates to a controller unit and methods for controlling an insulin pump. The controller unit includes a user input that receives a gain factor. The gain factor has been calculated based on historical data in relation to a patient. The controller unit includes a measurement input for receiving data representative of a measured blood glucose level for the patient. Processing logic of the controller unit is configured to apply the measured blood glucose level to a pancreatic beta-cell insulin secretion computational model to predict an insulin output level, apply the gain factor to the predicted insulin output level to determine a patient insulin deficiency level, and calculate a control signal for controlling the insulin output level of the insulin pump based on the patient insulin deficiency level.; Methods are provided for optimising the gain factor based on the historical data in relation to the patient.
Owner:GENE ONYX
Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems
InactiveUS20090298169A1Promote differentiationHigh activityPancreatic cellsArtificial cell constructsGerm layerPancreas
The invention relates to methods that allow for the efficient differentiation to form pancreatic endoderm cells from pluripotent stem cells such as human embryonic stem cells and definitive endoderm cells. The invention is directly applicable to the ultimate generation of pancreatic beta cells that could be used as part of a therapy to treat or even cure diabetes. Additionally, the present invention may be used to generate liver endoderm cells from human embryonic stem cells and definite endoderm cells as well. This invention relates to a method for generating definitive endoderm and pancreatic endoderm cells from stem cells, preferably human embryonic stem cells using defined media in the absence of feeder cells. A simply two step procedure to provide pancreatic endoderm cells from embryonic stem cells represents further embodiments of the present invention.
Owner:UNIV OF GEORGIA RES FOUND INC
Preparation method for mulberry leaf polysaccharide hypoglycemic active component
The invention provides a preparation method for a mulberry leaf polysaccharide hypoglycemic active component, and belongs to the technical field of natural medicine extraction. After water extraction, deproteinization, ethanol extraction, and freeze drying are conducted to dry mulberry leaf powder of 100g, mulberry leaf total polysaccharides of 3.2896g are obtained, obtaining rate is 3.29%, and purity is 92.81%. The obtained polysaccharide sample respectively undergoes diethyl-aminoethanol (DEAE)-52 cellulose column chromatography and SephadexG-100 column chromatography purification so as to obtain three uniform polysaccharide single components, namely a mulberry leaf polysaccharide I (MLPI), an MLP II, and an MLP III. Each component of the mulberry leaf polysaccharide has good effect to weight-losing and improvement of hyperglycemia symptoms of a diabetic rat, can repair injury of pancreas islet, facilitates pancreatic beta cells of the diabetic rat to secrete insulin, is free of toxic and side effect, and can be used for treating diabetes mellitus.
Owner:SHANDONG AGRICULTURAL UNIVERSITY
New plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
ActiveUS20100322850A1Evaluate effectivenessEarly detectionDisease diagnosisDiagnostic recording/measuringDiseaseDendritic cell
The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.
Owner:UNIV LIBRE DE BRUXELIES +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com